Selloff or Market Correction? Either Way, Here's What to Do Next!See Overvalued Stocks

Guggenheim cuts Pfizer shares target, keeps Buy rating ahead of guidance

Published 11/12/2024, 14:48
Guggenheim cuts Pfizer shares target, keeps Buy rating ahead of guidance

Guggenheim cuts Pfizer shares target, keeps Buy rating ahead of guidance

PFE
2.29%

On Wednesday, Guggenheim adjusted its financial outlook for shares of Pfizer Inc. (NYSE: NYSE:PFE), reducing the price target to $33.00 from the previous $35.00, but the firm continues to recommend a Buy rating for the pharmaceutical giant's stock. The revision comes in anticipation of Pfizer releasing its initial fiscal year 2025 guidance on December 17, before market opening.

The adjustment by Guggenheim follows a review of the latest prescription data for Pfizer's key products in the first two months of the fourth quarter of 2024.

The firm has updated its company model post discussions with Pfizer's Investor Relations and has lowered sales estimates for significant products including Comirnaty, Paxlovid, and Abrysvo. Additionally, Guggenheim has reduced its operating expense projections, particularly for the later years in their model.

Guggenheim's model changes have led to a decrease in their forecast for Pfizer's earnings per share (EPS) for fiscal year 2024 to $2.99, down from $3.03, and for fiscal year 2025 to $2.88, a significant drop from the previously predicted $3.22. The firm attributes approximately a 30 cent EPS headwind in fiscal year 2025 to certain benefits that will not recur, having positively impacted the company's results in fiscal year 2024.

The updated discounted cash flow (DCF) analysis by Guggenheim has resulted in the new price target of $33. Despite the lowered expectations, Guggenheim suggests that investor expectations for Pfizer's fiscal year 2025 EPS guidance are somewhat below the current $2.90 consensus estimate from FactSet.

Investors are anticipating guidance to fall between $2.55 and $2.70, which could provide Pfizer with an opportunity to surpass and elevate estimates as the year progresses, albeit not to the extent seen in 2024.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Should you invest $2,000 in PFE right now?

With PFE making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed PFE alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including PFE, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is PFE poised for similar growth? Don't miss the opportunity to find out.

Reveal Undervalued Stocks Now

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.